Home Pipeline

Overview

MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly.

 

Program (Target) Potential Indication(s) First-in-Human (Phase 1) Proof-of-Concept
(Phase 2)
Pivotal Approved (a) Major Market Rights
Margetuximab
(HER2)
HER2+ Breast
placeholder
placeholder
placeholder
placeholder
Greater China
HER2+ Gastric/GEJ (+retifanlimab/tebotelimab)
placeholder
placeholder
Flotetuzumab
(CD123 × CD3)
Refractory AML
placeholder
placeholder
placeholder
Retifanlimab(b)
(PD-1)
NSCLC, Anal
placeholder
placeholder
placeholder
Greater China
Enoblituzumab
(B7–H3)
SCCHN (+retifanlimab/tebotelimab)
placeholder
Planned 1Q21

Greater China
Tebotelimab
(PD-1 × LAG-3)
Solid Tumors & Heme Malignancies
placeholder
placeholder
Greater China
MGD019
(PD-1 × CTLA-4)
MSS-Colorectal, NSCLC
placeholder
MGC018
(B7-H3)
mCRPR, TNBC, NSCLC
placeholder
IMGC936
(ADAM9)
Solid Tumors
placeholder
50/50 Collaboration

Oncology
HER2+ Breast
Phase 1 Phase 2 Pivotal Approved(a)
placeholder
placeholder
placeholder
placeholder
HER2+ Gastric/GEJ (+retifanlimab/tebotelimab)
Phase 1 Phase 2 Pivotal Approved
placeholder
Major Market Rights:

Greater China
Flotetuzumab (CD123 × CD3)
Refractory AML
Phase 1 Phase 2 Pivotal Approved
placeholder
placeholder
placeholder
Major Market Rights:
NSCLC, Anal
Phase 1 Phase 2 Pivotal Approved
placeholder
placeholder
placeholder
Major Market Rights:

Greater China
SCCHN (+retifanlimab/tebotelimab)
Phase 1 Phase 2 Pivotal Approved
Planned 1Q21
placeholder
Major Market Rights

Greater China
Tebotelimab (PD-1 × LAG-3)
Solid Tumors/Heme Mal.
Phase 1 Phase 2 Pivotal Approved
placeholder
placeholder
Major Market Rights

Greater China
MGD019 (PD-1 × CTLA-4)
MSS-Colorectal, NSCLC
Phase 1 Phase 2 Pivotal Approved
placeholder
Major Market Rights
MGC018 (B7-H3)
mCRPR, TNBC, NSCLC
Phase 1 Phase 2 Pivotal Approved
placeholder
Major Market Rights

IMGC936
(ADAM9)
Solid Tumors
Phase 1 Phase 2 Pivotal Approved
placeholder
Major Market Rights
50/50 Collaboration

“MGD” = DART “MGA” = Antibody“MGC” = ADC

(a) FDA Approved on 12/16/2020
(b) MacroGenics retains rights to develop its pipeline assets in combination w/retifanlimab and manufacture a portion of global clinical and commercial supply needs.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close